[go: up one dir, main page]

CY1115777T1 - Βελτιωμενα κυστιδια εξωτερικης μεμβρανης βακτηριων - Google Patents

Βελτιωμενα κυστιδια εξωτερικης μεμβρανης βακτηριων

Info

Publication number
CY1115777T1
CY1115777T1 CY20141100736T CY141100736T CY1115777T1 CY 1115777 T1 CY1115777 T1 CY 1115777T1 CY 20141100736 T CY20141100736 T CY 20141100736T CY 141100736 T CY141100736 T CY 141100736T CY 1115777 T1 CY1115777 T1 CY 1115777T1
Authority
CY
Cyprus
Prior art keywords
pellet
collecting
detergent
outer membrane
membrane vesicles
Prior art date
Application number
CY20141100736T
Other languages
English (en)
Inventor
Mariagrazia Pizza
Davide Serruto
Rino Rappuoli
Original Assignee
Novartis Vaccines And Diagnostics S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9943238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115777(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines And Diagnostics S.R.L. filed Critical Novartis Vaccines And Diagnostics S.R.L.
Publication of CY1115777T1 publication Critical patent/CY1115777T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Οι υπάρχουσες μέθοδοι της προηγούμενης τεχνικής για την παρασκευή μηνιγγιτικοκοκκικών ΟΜV παρασκευάσματος εμπλέκουν την χρήση απορρυπαντικού κατά την διάρκεια της διάσπασης της βακτηριακής μεμβράνης. Σύμφωνα με την εφεύρεση, η διάσπαση της μεμβράνης ουσιαστικά γίνεται απουσία απορρυπαντικού. Τα ΟΜV που προκύπτουν που διατηρούν σημαντικά ανοσογονικά συστατικά, ιδιαίτερα (i) την προστατευτική πρωτεΐνη επιφανείας ΝspΑ (ii) την πρωτεΐνη ΝΜΒ2132 και (iii) την πρωτεΐνη ΝΜΒ 1870. Η μέθοδος της εφεύρεσης τυπικά εμπλέκει τα ακόλουθα βασικά στάδια : (α) επεξεργασία βακτηριακών κυττάρων ουσιαστικά απουσία απορρυπαντικού, (β) φυγοκέντρηση της σύνθεσης του σταδίου (α) για τον διαχωρισμό των κυστιδίων της εξωτερικής μεμβράνης από τα επεξεργασμένα κύτταρα και από τα κυτταρικά κατάλοιπα και συλλογή του υπερκειμένου, (γ) εκτέλεση φυγοκέντρησης υψηλής ταχύτητας του υπερκειμένου του σταδίου (β) και συλλογή των κυστιδίων της εξωτερικής μεμβράνης σε ένα ίζημα , (δ) αναδιάλυση του ιζήματος από το στάδιο (γ) σε ένα ρυθμιστικό διάλυμα, (ε) εκτέλεση μίας δεύτερης φυγοκέντρησης υψηλής ταχύτητας σύμφωνα με το στάδιο (γ), συλλογή κυστιδίων εξωτερικής μεμβράνης σε ένα ίζημα, (στ) αναδιάλυση του ιζήματος από το στάδιο (ε) σε ένα υδατικό διάλυμα.
CY20141100736T 2002-08-30 2014-09-11 Βελτιωμενα κυστιδια εξωτερικης μεμβρανης βακτηριων CY1115777T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0220194.5A GB0220194D0 (en) 2002-08-30 2002-08-30 Improved vesicles
EP07012893.9A EP1864679B1 (en) 2002-08-30 2003-09-01 Improved bacterial outer membrane vesicles

Publications (1)

Publication Number Publication Date
CY1115777T1 true CY1115777T1 (el) 2017-01-25

Family

ID=9943238

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20071101197T CY1107737T1 (el) 2002-08-30 2007-09-17 Βελτιωμενα κυστιδια εξωτερικης μεμβρανης βακτηριων
CY20131100752T CY1114570T1 (el) 2002-08-30 2013-09-02 Βελτιωμενα κυστιδια βακτηριακης εξωτερικης μεμβρανης
CY20141100736T CY1115777T1 (el) 2002-08-30 2014-09-11 Βελτιωμενα κυστιδια εξωτερικης μεμβρανης βακτηριων

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20071101197T CY1107737T1 (el) 2002-08-30 2007-09-17 Βελτιωμενα κυστιδια εξωτερικης μεμβρανης βακτηριων
CY20131100752T CY1114570T1 (el) 2002-08-30 2013-09-02 Βελτιωμενα κυστιδια βακτηριακης εξωτερικης μεμβρανης

Country Status (21)

Country Link
US (2) US20060166344A1 (el)
EP (5) EP2258388B1 (el)
JP (3) JP2006503822A (el)
CN (2) CN1688334A (el)
AT (1) ATE366117T1 (el)
AU (1) AU2003263534B2 (el)
BR (1) BRPI0314094A8 (el)
CA (1) CA2497165C (el)
CY (3) CY1107737T1 (el)
DE (1) DE60314756T2 (el)
DK (3) DK1534326T3 (el)
ES (4) ES2289351T3 (el)
FR (1) FR13C0046I2 (el)
GB (1) GB0220194D0 (el)
LU (1) LU92239I2 (el)
MX (1) MXPA05002316A (el)
NZ (1) NZ538673A (el)
PT (3) PT1534326E (el)
RU (1) RU2325184C2 (el)
SI (2) SI2258389T1 (el)
WO (1) WO2004019977A2 (el)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9906927A (pt) * 1998-01-14 2001-11-20 Chiron Spa Proteìnas de neisseria meningitidis
AU761495B2 (en) 1998-05-29 2003-06-05 Chiron Corporation Combination meningitidis B/C vaccines
CA2838395C (en) 1999-05-19 2016-07-19 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CN102172398A (zh) 2000-01-17 2011-09-07 诺华疫苗和诊断有限公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CU23377A1 (es) * 2003-11-04 2009-05-28 Ct De Ingenieria Genetica Y Biotecnologia Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes
GB0416120D0 (en) 2004-07-19 2004-08-18 Health Prot Agency Stable compositions containing OMV's
CA2576280A1 (en) 2004-08-13 2006-02-16 Barry J. Marshall Helicobacter pylori-based delivery system
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
JP4993750B2 (ja) 2005-01-27 2012-08-08 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 髄膜炎菌に起因する疾患に対する広域防御のための、ｇｎａ１８７０を基にした小胞ワクチン
DK1858919T3 (da) * 2005-02-18 2012-07-16 Novartis Vaccines & Diagnostic Immunogener fra uropathogen Escherichia coli
US20090074712A1 (en) * 2005-05-19 2009-03-19 Compton Methods for Treatment and Prevention of Infection
KR20130122810A (ko) 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
PT2200642E (pt) 2007-10-19 2012-05-30 Novartis Ag Formulações de vacinas meningocócicas
RU2475496C2 (ru) 2008-02-21 2013-02-20 Новартис Аг МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
EP2367568A2 (en) 2008-12-17 2011-09-28 Novartis AG Meningococcal vaccines including hemoglobin receptor
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
AU2010242905B2 (en) * 2009-04-30 2014-10-23 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHbp) and methods of use
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
US20110045528A1 (en) * 2009-08-20 2011-02-24 Srisuda Dhamwichukorn Apparatus and method for enhanced disruption and extraction of intracellular materials from microbial cells
EP2470205A1 (en) 2009-08-27 2012-07-04 Novartis AG Adjuvant comprising aluminium, oligonucleotide and polycation
BR112012004275A2 (pt) 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
WO2011027956A2 (ko) 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델
CN102480932B (zh) * 2009-09-01 2015-01-14 阿昂梅迪克斯公司 源于肠道共生细菌的细胞外小泡及利用其的疫苗、备选药物筛选方法
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
JP5988492B2 (ja) 2009-09-02 2016-09-07 ノバルティス アーゲー Ｔｌｒ活性モジュレーターを含む免疫原性組成物
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
EP2483390A2 (en) 2009-09-30 2012-08-08 Novartis AG Expression of meningococcal fhbp polypeptides
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
WO2011084549A1 (en) 2009-12-15 2011-07-14 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
JP5635690B2 (ja) 2010-07-01 2014-12-03 ポステック アカデミー‐インダストリー ファウンデーション 細菌由来マイクロベシクルを用いた癌治療及び癌診断方法
SI3831406T1 (sl) 2010-08-23 2024-08-30 Wyeth Llc Stabilne formulacije antigenov neisseria meningitidis RLP2086
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
JP6002763B2 (ja) * 2011-07-07 2016-10-05 デ スタート デル ネダーランデン、フェルト．ドール デ ミニスター ファン フェーウェーエス グラム陰性細菌の外膜小胞を、洗浄剤を含まずに生産するためのプロセス
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
EP2823312B1 (en) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US9808517B2 (en) 2012-04-06 2017-11-07 Cornell University Subunit vaccine delivery platform for robust humoral and cellular immune responses
EP2861247B1 (en) 2012-06-14 2020-12-09 GlaxoSmithKline Biologicals SA Vaccines for serogroup x meningococcus
EP2877492A1 (en) 2012-07-27 2015-06-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
CN104602705A (zh) 2012-09-06 2015-05-06 诺华股份有限公司 血清组b脑膜炎球菌和d/t/p的联合疫苗
EP3400960A1 (en) 2012-09-18 2018-11-14 GlaxoSmithKline Biologicals S.A. Outer membrane vesicles
BR112015018877A2 (pt) 2013-02-07 2017-08-22 Externautics Spa Método para preparar uma composição farmacêutica, e, composição farmacêutica imunogênica
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
SG10201907875TA (en) 2014-02-28 2019-09-27 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3298031B1 (en) 2015-05-18 2020-10-21 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
AU2016354444B2 (en) * 2015-11-10 2021-04-01 Ohio State Innovation Foundation Methods and compositions related to accelerated humoral affinity
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
JP7105768B2 (ja) 2016-10-28 2022-07-25 ヴェダンタ バイオサイエンシーズ インコーポレーテッド 細菌を保存するための方法および組成物
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
BR112019019440A2 (pt) * 2017-03-31 2020-04-14 Indian Council Medical Res vacina contra febre tifoide a base de vesículas de membrana externa de duas cepas diferentes de espécies de salmonella tifoide
JP7369690B2 (ja) 2017-09-08 2023-10-26 エヴェロ バイオサイエンシズ，インコーポレーテッド 細菌の細胞外小胞
US10793865B2 (en) 2018-06-05 2020-10-06 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Transferrable mechanism of generating inducible, BAR domain protein-mediated bacterial outer membrane extensions
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
KR102852282B1 (ko) 2018-11-06 2025-09-01 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
TW202045192A (zh) * 2019-02-22 2020-12-16 美商艾弗洛生物科技股份有限公司 細菌膜製劑
WO2021031270A1 (zh) * 2019-08-22 2021-02-25 四川大学 细菌膜囊泡及其分离制备系统和方法
CN110563829B (zh) * 2019-09-17 2021-03-26 中国人民解放军国防科技大学 用于调控脂质体囊泡行为、功能的反光蛋白体系及其应用
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
JP2023541876A (ja) 2020-09-11 2023-10-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 外膜小胞
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
WO2023097652A1 (en) * 2021-12-03 2023-06-08 National Center For Nanoscience And Technology An engineered cell and application thereof
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
ATE120093T1 (de) 1988-12-19 1995-04-15 Praxis Biolog Inc Meningococcales klasse i-aussenmembranprotein- vakzin.
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FI920131A0 (fi) 1989-07-14 1992-01-13 Praxis Biolog Inc Cytokin- och hormonbaerare foer konjugatvaccin.
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
US5993826A (en) 1993-03-02 1999-11-30 Board Of Regents, The University Of Texas Methods and compositions relating to useful antigens of moraxella catarrhalis
AU3630093A (en) 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FR2692592B1 (fr) * 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
NL9201716A (nl) 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
ES2145072T3 (es) * 1993-05-13 2000-07-01 American Cyanamid Co Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DK0710118T3 (da) * 1994-04-20 1999-08-09 Us Army Vaccine mod infektioner med gram-negative bakterier
EP0769019A1 (en) 1994-07-01 1997-04-23 Rican Limited Helicobacter pylori antigenic protein preparation and immunoassays
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
EP0841944A2 (en) 1995-08-04 1998-05-20 University Of Guelph Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
EP0909323B1 (en) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Helicobacter pylori bacterioferritin
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
JP5037747B2 (ja) 1997-01-30 2012-10-03 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 免疫応答を刺激するための吸着された抗原を有するマイクロパーティクルの使用
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
EP2172216A3 (en) 1997-03-10 2010-11-24 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
EP2085090A3 (en) 1997-06-06 2012-05-02 The Regents of the University of California Inhibitors of DNA immunostimulatory sequence activity
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US6451317B1 (en) * 1997-07-17 2002-09-17 Baxter International Inc. Immunogenic conjugates comprising a Group B meningococcal porin and an H influenzae polysaccharide
CA2300854C (en) 1997-08-21 2011-04-05 Peter Andre Van Der Ley Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
AU762606B2 (en) 1997-11-21 2003-06-26 Genset S.A. Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
WO1999028475A2 (en) 1997-11-28 1999-06-10 Genset Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
BR9906927A (pt) 1998-01-14 2001-11-20 Chiron Spa Proteìnas de neisseria meningitidis
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
NZ532665A (en) 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
AU1202200A (en) 1998-10-09 2000-05-01 Chiron Corporation Neisseria genomic sequences and methods of their use
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
AU1722300A (en) 1998-11-12 2000-05-29 Regents Of The University Of California, The Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
SI1150712T1 (sl) * 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
US7081244B2 (en) * 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
ES2298128T3 (es) 1999-02-22 2008-05-16 Health Protection Agency Composiciones de vacuna neisseriana y metodos.
AU4673099A (en) 1999-02-26 2000-09-14 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
IL145043A0 (en) 1999-03-19 2002-06-30 Smithkline Beecham Biolog Vaccine
US6245568B1 (en) * 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
AUPQ005499A0 (en) * 1999-04-30 1999-05-27 Townsend, Roy Leslie Printing process
DK1228217T3 (da) 1999-04-30 2013-02-25 Novartis Vaccines & Diagnostic Konserverede neisseria-antigener
CA2838395C (en) 1999-05-19 2016-07-19 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
CA2383110A1 (en) 1999-09-24 2001-03-29 Veronique Henderickx Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one non-ionic surfactant
EP1221971A2 (en) 1999-09-24 2002-07-17 SmithKline Beecham Biologics SA Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
CN102172398A (zh) 2000-01-17 2011-09-07 诺华疫苗和诊断有限公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
GB0007433D0 (en) * 2000-03-27 2000-05-17 Microbiological Res Authority Recombinant transferrin binding proteins
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
GB0017149D0 (en) 2000-07-12 2000-08-30 Chiron Spa Helicobacter pylori mutants
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US6753015B2 (en) 2000-09-28 2004-06-22 Chiron Corporation Microparticle compositions and methods for the manufacture thereof
IL154853A0 (en) 2000-10-27 2003-10-31 Chiron Spa Nucleic acids and proteins from streptococcus groups a & b
GB0103171D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2002330681C1 (en) 2001-07-26 2015-04-02 Glaxosmithkline Biologicals S.A. Vaccines comprising aluminium adjuvants and histidine
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
AU2003260357B2 (en) * 2002-08-02 2009-10-29 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB- Neisseria minigitidis

Also Published As

Publication number Publication date
ES2483592T3 (es) 2014-08-06
BR0314094A (pt) 2005-11-16
EP1534326B1 (en) 2007-07-04
PT1534326E (pt) 2007-10-17
AU2003263534B2 (en) 2010-08-05
JP2006503822A (ja) 2006-02-02
DE60314756T2 (de) 2008-03-06
US20150258188A1 (en) 2015-09-17
RU2005108994A (ru) 2006-02-10
CA2497165A1 (en) 2004-03-11
WO2004019977A2 (en) 2004-03-11
CN102188700A (zh) 2011-09-21
EP1864679B1 (en) 2014-06-18
ATE366117T1 (de) 2007-07-15
DK2258389T3 (da) 2013-08-26
CN1688334A (zh) 2005-10-26
CA2497165C (en) 2015-10-20
EP2258389B1 (en) 2013-06-05
BRPI0314094A8 (pt) 2018-04-03
GB0220194D0 (en) 2002-10-09
DE60314756D1 (de) 2007-08-16
PT2258389E (pt) 2013-08-22
NZ538673A (en) 2008-04-30
EP2258388B1 (en) 2014-08-13
DK1864679T3 (da) 2014-08-25
ES2423019T3 (es) 2013-09-17
CY1114570T1 (el) 2017-01-25
EP2258388A1 (en) 2010-12-08
EP1864679A2 (en) 2007-12-12
DK1534326T3 (da) 2007-10-22
JP2010150287A (ja) 2010-07-08
EP1534326A2 (en) 2005-06-01
JP2013139471A (ja) 2013-07-18
FR13C0046I2 (fr) 2014-05-16
CY1107737T1 (el) 2013-04-18
EP1864679A3 (en) 2008-04-02
FR13C0046I1 (el) 2013-09-06
RU2325184C2 (ru) 2008-05-27
ES2289351T3 (es) 2008-02-01
SI1864679T1 (sl) 2014-10-30
ES2520392T3 (es) 2014-11-11
EP2258390A1 (en) 2010-12-08
WO2004019977A3 (en) 2004-07-15
JP5808358B2 (ja) 2015-11-10
US20060166344A1 (en) 2006-07-27
MXPA05002316A (es) 2005-06-08
LU92239I2 (fr) 2013-09-04
PT1864679E (pt) 2014-09-25
EP2258389A1 (en) 2010-12-08
AU2003263534A1 (en) 2004-03-19
SI2258389T1 (sl) 2013-07-31

Similar Documents

Publication Publication Date Title
CY1115777T1 (el) Βελτιωμενα κυστιδια εξωτερικης μεμβρανης βακτηριων
JP2006503822A5 (el)
DE60045034D1 (de) Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen
EA201790287A3 (ru) Охлаждение и обработка материалов
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
BR0108711A (pt) Expressão heteróloga de proteìnas de neisseria
WO2005040349A3 (en) Immunogenic composition and method of developing a vaccine based on cyclophilin a binding site
CN104073537A (zh) 一种利用复合蛋白酶制备活性胶原蛋白的方法
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
WO2004060303A3 (en) Methods and reagents for the enhancement of virus transduction in the bladder epithelium
CA2386125A1 (en) Method of improving gene transfer efficiency into plant cells
CA2386126A1 (en) Method of improving gene transfer efficiency into plant cells
EP1229111A3 (en) Cultured cells of Ficus stipulata thunb. (= Ficus thunbergii) and a method for culturing tissues of the Ficus stipulata by using said cultured cells
AU2003246369A1 (en) Vaccination with immuno-isolated cells producing an immunomodulator
WO2002043651A3 (en) Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
RU2002132049A (ru) Способ получения липополисахаридов
RU2003134680A (ru) Способ получения эндонуклеазы рестрикции spm i
RU2231364C2 (ru) Способ получения капсульного вещества возбудителя мелиоидоза
Jamalzade et al. Genetic diversity of Brenneria nigrifluens strains in north of Iran (margin of Caspian sea)
ATE437177T1 (de) Hsp60 von arthrobacter
CN102041253A (zh) 一种蛇毒蛋白的提取工艺
CN120899894A (zh) 一种鳜鱼isknv mcp疫苗高渗浸泡免疫的构建方法及应用
WO2002066053A3 (en) Method of treating or preventing disease characterized by cryptococcus neoformans infection
XIRAB The Last Trade Caravan in Tibet (Ⅷ): MISFORTUNE BEFALLS KELSANG WANGDU'S FAMILY
RU2006124895A (ru) СПОСОБ ВЫДЕЛЕНИЯ БЕЛКОВ ТОКСИН-КОРЕГУЛИРУЕМЫХ ПИЛЕЙ АДГЕЗИИ И OmpU ХОЛЕРНОГО ВИБРИОНА КЛАССИЧЕСКОГО БИОВАРА